Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.64 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324805 | 1.00 | NOD1 (0.64) | NOD1SLC6A5EPHX2GPR84FFAR1 | |
| SCHEMBL11736294 | 0.93 | NOD1 (0.58) | NOD1SLC6A5FOLH1 | |
| SCHEMBL11736289 | 0.93 | NOD1 (0.58) | NOD1SLC6A5FOLH1 | |
| SCHEMBL9267642 | 0.86 | NOD1 (0.68) | NOD1SLC6A5GPR84FFAR1 | |
| SCHEMBL11739515 | 0.85 | NOD1 (0.49) | NOD1SLC6A5FOLH1 | |
| SCHEMBL11739510 | 0.85 | NOD1 (0.49) | NOD1SLC6A5FOLH1 | |
| SCHEMBL19840648 | 0.84 | NOD1 (0.87) | NOD1SLC6A5EPHX2 | |
| SCHEMBL17849921 | 0.84 | NOD1 (0.87) | NOD1SLC6A5EPHX2 | |
| SCHEMBL9258754 | 0.84 | NOD1 (0.81) | NOD1SLC6A5EPHX2 | |
| SCHEMBL4611531 | 0.84 | NOD1 (0.76) | NOD1SLC6A5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179538-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | AMINOLOGICS CO., LTD. (KR) | 2021-06-17 | — | — | US | disclosed |
| EP-3725766-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | Aminologics Co., Ltd. (KR) | 2020-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179538-A1 | METHOD FOR PRODUCING 2-OCTYLGLYCINE ESTER HAVING OPTICAL ACTIVITY | GNMT, UGT8, OPRM1 | NOD1 935/4885SLC6A5 501/4885EPHX2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.